|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NR2F2-AS1 |
Gene summary for NR2F2-AS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NR2F2-AS1 | Gene ID | 644192 |
| Gene name | NR2F2 antisense RNA 1 | |
| Gene Alias | NR2F2-AS1 | |
| Cytomap | 15q26.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 644192 | NR2F2-AS1 | C43 | Human | Oral cavity | OSCC | 3.94e-04 | -1.76e-01 | 0.1704 |
| 644192 | NR2F2-AS1 | C08 | Human | Oral cavity | OSCC | 4.38e-02 | -1.72e-01 | 0.1919 |
| 644192 | NR2F2-AS1 | EOLP-1 | Human | Oral cavity | EOLP | 6.36e-08 | 4.35e-01 | -0.0202 |
| 644192 | NR2F2-AS1 | NEOLP-1 | Human | Oral cavity | NEOLP | 3.92e-02 | 3.10e-01 | -0.0194 |
| 644192 | NR2F2-AS1 | NEOLP-2 | Human | Oral cavity | NEOLP | 5.39e-10 | 5.51e-01 | -0.0196 |
| 644192 | NR2F2-AS1 | NEOLP-3 | Human | Oral cavity | NEOLP | 5.61e-12 | 5.02e-01 | -0.0191 |
| 644192 | NR2F2-AS1 | SYSMH1 | Human | Oral cavity | OSCC | 1.77e-03 | -1.75e-01 | 0.1127 |
| 644192 | NR2F2-AS1 | SYSMH2 | Human | Oral cavity | OSCC | 1.77e-03 | -1.76e-01 | 0.2326 |
| 644192 | NR2F2-AS1 | SYSMH3 | Human | Oral cavity | OSCC | 3.94e-04 | -1.76e-01 | 0.2442 |
| 644192 | NR2F2-AS1 | SYSMH4 | Human | Oral cavity | OSCC | 8.35e-04 | -1.76e-01 | 0.1226 |
| 644192 | NR2F2-AS1 | SYSMH6 | Human | Oral cavity | OSCC | 1.77e-03 | -1.73e-01 | 0.1275 |
| 644192 | NR2F2-AS1 | ATC11 | Human | Thyroid | ATC | 3.71e-05 | 4.02e-01 | 0.3386 |
| 644192 | NR2F2-AS1 | ATC12 | Human | Thyroid | ATC | 2.77e-07 | 1.65e-01 | 0.34 |
| 644192 | NR2F2-AS1 | ATC13 | Human | Thyroid | ATC | 9.88e-36 | 5.20e-01 | 0.34 |
| 644192 | NR2F2-AS1 | ATC3 | Human | Thyroid | ATC | 5.97e-08 | 4.46e-01 | 0.338 |
| 644192 | NR2F2-AS1 | ATC4 | Human | Thyroid | ATC | 1.63e-06 | 1.68e-01 | 0.34 |
| 644192 | NR2F2-AS1 | ATC5 | Human | Thyroid | ATC | 1.12e-33 | 5.44e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |